Will Ganley is currently Head of Computational Pharmaceutics at Nanopharm Ltd, An Aptar Pharma Company (UK). He holds an MChem from the University in Southampton where he studied metallic nanoparticles suspensions for sensing and PhD from the University of Bristol where he studied the structure and rheology of gels formed by non-spherical colloidal particles.
Following this Will took up a postdoc position at the University of Bath in Professor Rob Price’s group where he was part of the INFORM2020 consortium, a multi-institution industrial collaboration aiming to combine novel characterisation and computational modelling techniques to understand dry powder inhaler from the scale of molecules through to finished products. During this time he conducted in vitro characterisation of inhaled pharmaceutical products and developed in silico physicochemical, pharmacokinetic and statistical models to augment his laboratory testing.
In 2019 Will joined Nanopharm to lead the Computational Pharmaceutics group where he continues to develop computational solutions to power up the data generated in Nanopharm’s labs. His team exploration of novel techniques for the characterisation of inhaled products and uses mechanistic and statistical models to make predictions and squeeze the maximum amount of information out of every project. Their work supports products development, clinical and regulatory projects.
Will has presented work on physical chemistry and pharmaceutics at multiple international conferences. He has published 6 peer reviewed research articles and was awarded both the Faculty of Science Prize for the Physical Sciences and the Best Doctoral Research Thesis Prize for the Faculty of Science for his PhD.